The Realities of “Right to Try”
In May 2018, President Donald Trump signed into law the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017.1 The law amends the Federal Food, Drug, and Cosmetic...
Online Exclusives
MSKCC Researchers Correct Financial Disclosures
After reports from ProPublica and The New York Times revealed that scientists from Memorial Sloan Kettering Cancer Center (MSKCC) failed to disclose financial relationships...
Congress Passes Bills Banning Gag Clauses
Congress has passed two bills to ban “gag clauses” in contracts between pharmacies and insurance companies or pharmacy benefit managers (PBMs). The legislation, supported...
News
From the Blood Journals
Examining Hospice Use Among Transfusion-Dependent Patients With Leukemia
Since 2001, more patients with leukemia are receiving hospice services, which has been associated with improved quality of life, according to an analysis published...
Mapping Silent Cerebral Infarcts in Children With Sickle Cell Anemia
Children with sickle cell anemia (SCA) are at risk of developing cerebral ischemia, including a high prevalence of silent cerebral infarcts (SCI), which can...
Multimedia
Pulling Back the Curtain: Vip Viprakasit, MD, DPhil
In more from our interview with Dr. Viprakasit, he speaks about the advantages of working in a limited-resource setting and the importance of international...
Let’s Get Cooking: Jonathan Hoggatt, PhD
In more from our interview with Dr. Hoggatt, he talks about the chocolate chip cookie experiment that started his obsession with cooking.
Pulling Back the Curtain: Richard W. Childs, MD
Hear more from our interview with Dr. Childs, where he talks about his inventive career in medicine and the best and worst parts of his...
LentiGlobin Gene Therapy Possibly Safe for Severe Sickle Cell Disease
Interim data from a phase I study of LentiGlobin BB305 in patients with severe sickle cell disease (SCD) suggest that the gene therapy was...
On Location
From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal Residual Disease
During their presentations, MHM speakers will be asking the audience how they would respond to...
From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera
During their presentations, MHM speakers will be asking the audience how they would respond to...
From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL
During their presentations, MHM speakers will be asking the audience how they would respond to...
Researchers Define Long-Term Outcomes of Cancer-Associated Thrombosis
Patients diagnosed with cancer-associated thrombosis (CAT) remain at a high risk for recurrent venous thromboembolism...
Romiplostim Helps Patients With Glioblastoma and Thrombocytopenia Stay on Treatment
Temozolomide (TMZ) is part of the standard treatment for patients with glioblastoma, but the drug...
APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML
In a small phase IB/II trial presented at the 23rd Congress of the European Hematology...
Latest Headlines
ASH Directions
Announcing the 2018 Honorific and Mentor Award Recipients, and more
Announcing the 2018 Honorific and Mentor Award Recipients!
ASH will recognize these distinguished leaders in hematology through awards and special lectures at the 60th ASH...
Start Planning Now for the 60th ASH Annual Meeting and Exposition, and more
Start Planning Now for the 60th ASH Annual Meeting and Exposition
The preliminary program for the 2018 ASH annual meeting is now available online. The...
Jonas Sokolof Named Director of NYU Langone’s New Rehab Program for Cancer Survivors, and...
Jonas Sokolof Appointed Director of NYU Langone’s New Rehabilitation Program for Cancer Survivors
NYU Langone’s Rusk Rehabilitation has opened the Division of Oncological Rehabilitation, launching...
NIH Awards $24 Million to UT Health San Antonio, and more
Remembering Michael C. Lill (1959-2018)
Michael C. Lill, MD, passed away on June 19, 2018, after a long battle with cancer. Dr. Lill was born...
Fred Hutch Scientists Receive $20 Million for Leukemia Projects, and more
Remembering Alan Rabson (1926 – 2018)Alan Rabson, MD, a long-time leader at the National Cancer Institute (NCI), passed away on July 4, 2018, at...
The Realities of “Right to Try”
In May 2018, President Donald Trump signed into law the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of...
Breakthroughs in Gene Therapy for Hemophilia
Gene therapy for hemophilia is here – and it’s working. The field is advancing at a steady clip: Results from recent trials of this...
The Code of Misconduct
Scientific misconduct is more than falsification, fabrication, and plagiarism – and harder to identify.
In 1998, Andrew Wakefield, MD, and co-authors investigated a cohort of...
